PSMA PET/CT Transforms Salvage Radiation for Biochemical Recurrence
Paradigm Shift for Evaluating, Treating Biochemical Recurrence in Prostate Cancer | MedPage Today New Long-Term Data Shows Promise BLUF (Bottom Line Up Front): A landmark 5-year study from UCLA demonstrates that PSMA PET/CT imaging can revolutionize treatment for prostate cancer patients experiencing biochemical recurrence after surgery. Nearly three-quarters of patients remained metastasis-free at 5 years when salvage radiation therapy was guided by this advanced imaging, with an impressive 97% overall survival rate. This represents a paradigm shift from "one-size-fits-all" to precision-guided treatment, allowing doctors to see cancer at PSA levels as low as 0.4 ng/mL—far earlier than conventional imaging—and tailor radiation therapy accordingly. A Game-Changing Approach to Rising PSA After Surgery For the 20-40% of prostate cancer patients who experience rising PSA levels after radical prostatectomy, the question has always been: where is the cancer, and how should we t...